Abstract: Nucleic acids comprising a nucleic acid moiety and two or more transfection enhancer elements (TEE's) according to the general formula (I): Hydrophobic moiety—pH-responsive hydrophilic moiety, wherein said pH sensitive hydrophilic moiety of said TEE is independently a weak acid having a pka of between 4 and 6.5 or is a zwitterionic structure comprising a combination of acidic groups with weak basis having a pKa of between 4.5 and 7.

Abstract: This invention provides novel compositions comprising substituted polyamines as acid gas scrubbing solutions and methods of using the compositions in an industrial system. The invention relates to the use of such polyamine compounds in industrial processes to remove acidic contaminants from natural and industrial fluid streams, such as natural gas, combustion gas, natural gas, synthesis gas, biogas, and other industrial fluid streams. The compositions and methods of the invention are useful for removal, absorption, or sequestration of acidic contaminants and sulfide contaminants including CO2, H2S, RSH, CS2, COS, and SO2.

Abstract: Absorption medium for acid gases comprising an oligoamine (A) of the general formula (I) and a primary or secondary alkanolamine (B) of the general formula (II) in which the weight ratio of oligoamine (A) to the primary or secondary alkanolamine (B) is 0.2 to 4, and also the process for removing acid gases from a gas stream by contacting the gas stream at a pressure of 0.05 to 10 MPa abs with an aqueous solution brought to and maintained at a temperature of 20 to 80° C. of said absorption medium.

Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.

Abstract: A method of preparing polyalkylated oligoalkylenepolyamines is provided. The method includes contacting oligoalkylenepolyamine with a reagent composition comprising (a) alkyl bromide and/or alkyl chloride; (b) a basic agent; and (c) iodide salt. The alkylation reaction may be carried out in a polar, aprotic organic solvent.

Abstract: A compound having formula (I) wherein R1, R2, R3, R4, R5 and R6 independently are hydrogen, C1-C10 alkyl, C5-C10 cycloalkyl, C6-C10 aryl or C7-C20 aralkyl; X is a difunctional group selected from the group consisting of C2-C20 alkyl, C5-C20 cycloalkyl, C6-C10 aryl, C8-C20 aryl alkyl, C4-C20 heteroalkyl or C10-C20 aryl heteroalkyl.

Abstract: Provided is a low-cost, highly active, environmentally friendly living radical polymerization catalyst which does not require a radical initiator. An organic compound having an oxidation-reduction capability is used as a catalyst. Even if a radical initiator is not used, a monomer can be subjected to a radical polymerization to obtain a polymer having narrow molecular weight distribution. The cost of the living radical polymerization can be remarkably reduced. It is made possible to prevent adverse effects of using a radical initiator. The present invention is significantly more environmentally friendly and economically excellent than conventional living radical polymerization methods, due to advantages of the catalyst such as low toxicity of the catalyst, low amount of the catalyst necessary, high solubility of the catalyst, mild reaction conditions, and no coloration/no odor (which do not require a post-treatment for a molded article), etc.

Abstract: Electronic inks are disclosed herein. One embodiment of the electronic ink includes a non-polar carrier fluid, a plurality of negatively charged colorant particles dispersed in the non-polar carrier fluid, a small molecular additive, and a charge director. Each of the negatively charged colorant particles includes a surface modified with an acidic functional group. The small molecular additive has at least two branches, each of which includes nitrogen or oxygen atoms.

Abstract: The invention relates to the use of spermidine or a pharmaceutically acceptable derivative thereof as the active principle in a pharmaceutical, cosmetic or dietetic composition. The composition is used for promoting pigmentation of the hair, particularly the shaft of the hair. The invention also relates to the composition which promotes this pigmentation effect, the composition containing spermidine or a derivative thereof (such as a salt) as an active principle and is intended for topical or oral administration.

Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Abstract: Disclosed are cationic lipid compounds and compositions of lipid aggregates for delivery of macromolecules and other compounds into cells. The compounds can be used alone or in combination with other compounds to prepare liposomes and other lipid aggregates suitable for transfection or delivery of compounds to target cells, either in vitro or in vivo. The compounds are preferably polycationic and preferably form highly stable complexes with various anionic macromolecules, particularly polyanions such as nucleic acids. These compounds have the property, when dispersed in water, of forming lipid aggregates which associate strongly, via their cationic portion, with polyanions. Also disclosed are intermediates for preparing the compound and compositions of the invention and methods of using the compounds to introduce other compounds into cells.

Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

Abstract: The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2? group, wherein the N2O2? group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.

Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

Abstract: The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N2O2— group, wherein the N2O2— group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.

Abstract: Polyamine, polyamine/guanidino, and polyamine/biguanide compounds bearing allene, propargyl, cyclopropyl, and other reactive moieties are disclosed. The compounds are useful as irreversible inhibitors of the enzyme lysine-specific demethylase-1 and for the treatment of cancer.

Abstract: Herein are disclosed adducts of amines and polycarboxylic acids, and methods of making such adducts. Such adducts can be used to remove cyanogen chloride. Also disclosed are methods of providing such adducts on supports to form filter media. Also disclosed are methods of combining such filter media with catalysts and/or with porous polymeric webs to form filter systems.

Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.

Abstract: The invention relates to a process for the preparation of onium alkylsulfates by reaction of an onium halide with a symmetrically substituted dialkyl sulfate, in which the alkyl group can have 1 to 14 C atoms, with an asymmetrically substituted dialkyl sulfate, in which one alkyl group can have 4 to 20 C atoms and the second alkyl group denotes methyl or ethyl, with an alkyl trialkylsilyl sulfate, with an alkyl acyl sulfate or with an alkyl sulfonyl sulfate, where the reaction with a dialkyl sulfate is carried out at room temperature.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.

Abstract: There are provided multi-chain lipophilic polyamine compounds and derivatives thereof, pharmaceutical formulations comprising the same, method of making and using said compounds or formulations.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: In another exemplary embodiment, an amine functional curing agent has an Amine Hydrogen Functionality (AHF) of at least 7 and an Amine-Hydrogen Equivalent Weight (AHEW) of at least about 50.

Abstract: The present invention provides unbranched aliphatic polyamines for use in therapy, particularly for use in the treatment of psoriasis and compositions containing polyamines.

Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.

Abstract: The embodiments of the invention relate to a multifunctional lithiated amine-containing compound comprising at least two molecules of lithiated amine in a molecule of the compound. In one embodiment, the compound has a formula where x is an integer of 1 or more, Q is (a) an element selected from the group consisting of O, S, N, P and Si or (b) an alkylene group having from 1 to 20 methylene groups, and R1 and R2 are the same or different and are selected from the group consisting of alkyls, cycloalkyls and aralkyls containing from 1 to 20 carbon atoms. In another embodiment, the compound comprises cyclic lithio amines and has a formula: where x is 1 or more, R3, R4 and R5 are the same or different and represent alkylene groups containing from 3 to 20 carbon atoms.

Abstract: A compound of formula (I): wherein k is 1 or 2; Y is —CH2CH(CF3)2 or —(CH2)nCF; X is hydrogen, —(CH2)nRf, or —C(O)[CF(A)]p-B—Rf, wherein B is a covalent bond, —O— or —(CH2)m—; A is —F or —CF3; and each Rf is independently C1 to C6 perfluorinated alkyl, optionally interrupted by one or more oxygens; Ro is Ro1 or is an alkyl having from about 10 to about 100 carbon atoms, interrupted or substituted by one or more hydrophilic groups; R is hydrogen or a C1 to C4 alkyl; and Ro1 is an aliphatic group of from about 10 to about 100 carbon atoms, interrupted by about from about 5 to about 50 ether oxygens; provided that 1) when Y is —(CH2)nRf, Ro is Ro1; 2) when X is hydrogen, Y is —CH2CH(CF3)2; and 3) when X is —(CH2)nRf and Y is —(CH2)nRf, Ro is Ro1.

Abstract: Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

Abstract: According to the invention, a slow setting bitumen-aggregate mix for cold paving is manufactured by a) preparing a cationic oil-in-water emulsion of bitumen in the presence of an emulsifier containing i) a tertiary polyamine selected from the group consisting of a di(C2-C3 alkylene)triamine, a tri(C2-C3 alkylene)tetraamine, a tetra(C2-C3 alkylene)pentaamine, a penta(C2-C3 alkylene)hexaamine, a hexa(C2 C3 alkylene)heptaamine or a mixture thereof, which amine compounds have only tertiary amine groups and contain one or two aliphatic groups with 8-22 carbon atoms, bound to a nitrogen atom, while the remaining nitrogen substituents are methyl groups and ii) an acid present in such an amount that the aqueous emulsion obtains a pH value from 1-6, preferably 1.5-5, and b) mixing the aqueous emulsion obtained with a solid aggregate.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)l, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and w

Abstract: The invention relates to a process for the preparation of onium salts with dialkylphosphate, dialkylphosphinate or (O-alkyl)alkyl- or alkylphosphonate anions by reaction of an onium halide with a triallyl phosphate, alkyl dialkylphosphinate, dialkyl alkylphosphonate or trialkylsilyl ester or mixed alkyl trialkylsilyl ester of phosphoric, dialkylphosphinic or alkylphosphonic acid.

Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.

Abstract: Methods and systems for modifying a polymer are disclosed herein. A matrix is generally provided having a surface thereof, wherein the matrix comprises a plurality of hyperbranched polymers. The plurality of hyperbranched polymers can be chemically bound to a plurality of surfactants or order to modify the surface and produce a polymeric material thereof. The surface is tailored with a plurality of functional groups that self-assemble and are deliverable to the surface of the solution, including interfaces thereof, thereby permitting a high-density assembly of functional groups to operate in concert with one another in order to generate a modified surface thereof. The polymeric material produced thereof can be reversibly adaptable to environmental conditions through a blooming of varying surface functional group to the surface of the solution.

Abstract: This invention discloses a process for manufacturing an elastomeric article by liquid injection molding, said process comprising the steps of: (I) heating a curable composition comprised of (1) a liquid polymer comprised of repeat units that are derived from a conjugated diolefin monomer, wherein said liquid polymer has a weight average molecular weight which is within the range of 5,000 to 100,000, and wherein the liquid polymer is functionalized with an amine moiety, (2) a carbonyl inhibited platinum catalyst, and (3) a tetrakis(dialkyl siloxy) silane crosslinking agent, to a temperature which is within the range of 30° C. to 100° C.; (II) injecting the heated curable composition into a mold at a temperature which is within the range of 100° C. to 210° C. to produce the elastomeric article; and (III) removing the elastomeric article from the mold.

Abstract: Tertiary amines useful as catalysts for preparing polyurethane foams are provided. Tertiary amines are employed to catalyze the trimerization reaction of isocyanates and the reaction between isocyanates and active hydrogen-containing compounds, such as a polyol and/or a blowing agent. Such tertiary amine has the general formula wherein R1, R2, Y, Z, and n are defined herein.

Abstract: Oligoamine compounds with anti-cancer and anti-proliferative activity are provided, as well as methods for making and using the compounds. The compounds are shown to be active against prostate cancer cell lines and against prostate cancer tumors in mice. The compounds are also useful in treatment of breast cancer and other cancers.

Abstract: Compositions and methods for improved delivery of macromolecules into eukaryotic cells are provided. Fusogenic peptides from fusion proteins of non-enveloped viruses enhance the efficiency of transfection of eukaryotic cells mediated by transfection agents such as cationic lipids, polycationic polymers such as PEI and dendrimers. These fusogenic peptides are used as part of a transfection complex that efficiently delivers a macromolecule, for example, a nucleic acid, into a eukaryotic cell. Novel cationic lipids and compositions of cationic lipids also are provided that may be used for the introduction of macromolecules such as nucleic acids, proteins and peptides into a variety of cells and tissues. The lipids can be used alone, in combination with other lipids and/or in combination with fusogenic peptides to prepare transfection complexes.

Abstract: Disclosed are compounds capable of facilitating transport of biologically active agents or substances into cells having the general structure: wherein Q is selected from the group consisting of N, O and S; L is any bivalent organic radical capable of linking each Q, such as C, CH, (CH2)I, or {(CH2)i-Y—(CH2)j}k, wherein Y is selected from the group consisting of CH2, an ether, a polyether, an amide, a polyamide, an ester, a sulfide, a urea, a thiourea, a guanidyl, a carbamoyl, a carbonate, a phosphate, a sulfate, a sulfoxide, an imine, a carbonyl, and a secondary amino group and wherein Y is optionally substituted by —X1-L?-X2-Z or -Z; R1-R6, independently of one another, are selected from the group consisting of H, —(CH2)p-D-Z, an alkyl, an alkenyl, an aryl, and an alkyl or alkyl ether optionally substituted by one or more of an alcohol, an aminoalcohol, an amine, an amide, an ether, a polyether, a polyamide, an ester, a mercaptan, an alkylthio, a urea, a thiourea, a guanidyl, or a carbamoyl group, and w

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.

Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.

Abstract: Corrosion inhibitor and method of protecting metallic materials in strongly alkaline medium by means of a corrosion inhibitor, characterized in that it contains an amine containing at least one CH group bound to the nitrogen.

Abstract: An aminated polyamine having the formula: or its possible stereoisomers or a salt thereof with a pharmaceutically acceptable acid wherein: R1 and R4 may be the same or different and are alkyl, aryl, aryl alkyl or cycloalkyl, optionally having an alkyl chain interrupted by at least one etheric oxygen atom; R2 and R3 may be the same or different and are R1, R4 or H; N1, N2, N3 and N4 are nitrogen atoms capable of protonation at physiological pH's; ALK1, ALK2 AND ALK3 may be the same or different and are straight or branched chain alkylene bridging groups having 1 to 4 carbon atoms which effectively maintain a predetermined distance between the nitrogen atoms such that the polyamine upon uptake by the target cell, competitively functions in a manner wherein at least one of said bridging groups ALK1, ALK2 and ALK3 contains at least one —CH(NRH)— group which is not alpha- to either of the nitrogen atoms and R is H, alkyl, acyl or sulfonyl.

Abstract: The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

Abstract: A method for making N,N?-bis(3-aminopropyl)-1,2-ethylenediamine which comprises reacting acrylonitrile and ethylenediamine in about a 2:1 molar ratio to make a N,N?-bis(cyanoethyl)-1,2-ethylenediamine reaction product and hydrogenating the reaction product, the improvement for improving the selectivity of the reactions to N,N?-bis(2-cyanoethyl)-ethylenediamine and to N,N?-bis(3-aminopropyl)-1,2-ethylenediamine which comprises reacting acrylonitrile and ethylenediamine in the presence of 2-30 wt % water, based on total reactants.

Abstract: The invention relates to a method for producing bis-[(3-dimethylamino)propyl]amine (bisDMAPA) by continuously reacting 3-(N,N-dimethylamino)propylamine (DMAPA) in the presence of a heterogeneous catalyst. The inventive method is characterized by carrying out the reaction in a reaction column.

Abstract: Process for the preparation of ethylenamines, in particular diethylenetriamine (DETA), by continuous reaction of ethylenediamine (EDA) in the presence of a heterogeneous catalyst, where the reaction is carried out in a reaction column.

Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.

Abstract: According to the invention, a slow setting bitumen-aggregate mix for cold paving is manufactured by a) preparing a cationic oil-in-water emulsion of bitumen in the presence of an emulsifier containing i) a tertiary polyamine selected from the group consisting of a di(C2-C3 alkylene)triamine, a tri(C2-C3 alkylene)tetraamine, a tetra(C2-C3 alkylene)pentaamine, a penta(C2-C3 alkylene)hexaamine, a hexa(C2 C3 alkylene)heptaamine or a mixture thereof, which amine compounds have only tertiary amine groups and contain one or two aliphatic groups with 8-22 carbon atoms, bound to a nitrogen atom, while the remaining nitrogen substituents are methyl groups and ii) an acid present in such an amount that the aqueous emulsion obtains a pH value from 1-6, preferably 1.5-5, and b) mixing the aqueous emulsion obtained with a solid aggregate.

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.